← Back to feed

PureTech Health

PRTC · Main Market · Health Care · mcap £262m today

All announcements

All RNS · 61 Key events · 29

25 Sep 26

Holding(s) in Company
RNS 9792501 ↗
22 Sep 26

Half-year Results

Delivered significant progress across the portfolio, including Seaport's Nasdaq IPO, Celea's financing and Phase 3 trial initiation, and Gallop's positive Phase 1b data, successful End-of-Phase 1 meeting with the U.S.
RNS 9783228 ↗
21 Sep 26

PRTC's Gallop: Positive FDA Meeting & Fast Track

PureTech Announces Successful End-of-Phase 1 Meeting with U.S.
RNS 9780836 ↗
18 Sep 26

Holding(s) in Company
RNS 9780543 ↗
09 Sep 26

PRTC's SPTX: New Positive Phase 1 GlyphAllo Data

PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
RNS 9764173 ↗
04 Sep 26

Holding(s) in Company
RNS 9757395 ↗
04 Sep 26

Notice of Results
RNS 9755178 ↗
01 Sep 26

Total Voting Rights
RNS 9747160 ↗
28 Aug 26

Holding(s) in Company
RNS 9744374 ↗
25 Aug 26

PRTC's Celea:2 Deupirfenidone Presentations at ERS

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress
RNS 9739308 ↗
18 Aug 26

PDMR Notification RSU Vesting
RNS 9728357 ↗
03 Aug 26

Total Voting Rights
RNS 9699588 ↗
31 Jul 26

PDMR Notification RSU Vesting
RNS 9699371 ↗
17 Jul 26

PDMR Notification RSU Vesting Voting rights down

PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company") a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, announces that awards of restricted share units ("RSUs") granted by PureTech...
RNS 9675594 ↗
13 Jul 26

Celea Doses 1st Patient in Phase 3 IPF Trial

PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
RNS 9664249 ↗
09 Jul 26

Director/PDMR Shareholding Director buys

Robert Lyne Sharon Barber-Lui John LaMattina Michele Holcomb, Robert Lyne - Chief Executive Officer, Executive Director Sharon Barber-Lui - Interim Board Chair; Non-Executive Director John LaMattina - Non-Executive Director Michele Holcomb …
RNS 9659722 ↗
02 Jul 26

PRTC Launches Celea w/ $180M & Top Tier Syndicate

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
RNS 9648593 ↗
02 Jul 26

$180M & Asset Transfer

PureTech Announces Completion of $180 Million Financing for Founded Entity Celea Therapeutics to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
RNS 9648421 ↗
10 Jun 26

Result of AGM
RNS 9612206 ↗
09 Jun 26

PRTC's SPTX: New Positive GlyphAgo Ph1 Dosing Data

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
RNS 9607788 ↗
04 Jun 26

Holding(s) in Company
RNS 9602951 ↗
29 May 26

Holding(s) in Company
RNS 9592942 ↗
27 May 26

Holding(s) in Company
RNS 9588463 ↗
22 May 26

Holding(s) in Company
RNS 9583252 ↗
15 May 26

Correction - Holding(s) in Company
RNS 9569803 ↗
13 May 26

PRTC To Showcase Deupirfenidone at ATS Conference

PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference
RNS 9566625 ↗
08 May 26

Holding(s) in Company
RNS 9558237 ↗
07 May 26

Holding(s) in Company
RNS 9558077 ↗
01 May 26

PureTech's Seaport Prices Upsized IPO Nasdaq: SPTX

PureTech Founded Entity Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering
RNS 9548005 ↗
29 Apr 26

Final Results

PureTech Announces Annual Results for Year Ended December 31, 2025
RNS 9543048 ↗
29 Apr 26

PRTC Voluntarily Delists Nasdaq Depositary Shares

PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange
RNS 9542928 ↗
27 Apr 26

Holding(s) in Company
RNS 9540301 ↗
27 Apr 26

PRTC's Seaport Adds Neuropsychiatry Veteran to BOD

PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr.
RNS 9539828 ↗
24 Apr 26

Holding(s) in Company
RNS 9537987 ↗
22 Apr 26

PRTC's Gallop: Positive Ph1 Topline MDS & AML Data

PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)
RNS 9533090 ↗
16 Apr 26

Holding(s) in Company
RNS 9524626 ↗
16 Apr 26

Holding(s) in Company
RNS 9522658 ↗
13 Apr 26

Notice of Results
RNS 9515981 ↗
13 Apr 26

PRTC's Seaport Files for Proposed Nasdaq IPO

PureTech Health Founded Entity Seaport Therapeutics Files Registration Statement for Proposed Initial Public Offering
RNS 9515859 ↗
02 Apr 26

PRTC Publishes Phase 2b Deupirfenidone IPF Results

PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine
RNS 9506150 ↗
02 Apr 26

PRTC's Seaport: Positive Topline Ph1 for GlyphAgo

PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgoTM in Healthy Volunteers
RNS 9506044 ↗
01 Apr 26

Total Voting Rights
RNS 9501876 ↗
25 Mar 26

PRTC’s Seaport: GlyphAllo Paper Published

PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAlloTM (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans
RNS 9492341 ↗
13 Mar 26

PDMR Notification RSU Vesting
RNS 9474363 ↗
02 Mar 26

Total Voting Rights
RNS 9452029 ↗
25 Feb 26

PRTC to Present at Leerink Healthcare Conference

PureTech to Present at the Leerink Partners Global Healthcare Conference
RNS 9445521 ↗
19 Feb 26

PRTC's Deupirfenidone Granted FDA & EU ODD for IPF

PureTech Announces Orphan Drug Designations Granted by the U.S.
RNS 9439070 ↗
06 Jan 26

PureTech to Present at the JP Morgan Conference

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced that Robert Lyne, Chief Executive Officer, will...
RNS 9336546 ↗
18 Dec 25

PureTech Appoints Robert Lyne as CEO New CEO

PureTech Appoints Robert Lyne as Chief Executive Officer
RNS 9305007 ↗
10 Dec 25

Results of AGM on June 16, 2025 – Update Statement

Results of Annual General Meeting on June 16, 2025 - Update Statement
RNS 9288757 ↗
10 Dec 25

Holding(s) in Company
RNS 9288740 ↗
08 Dec 25

Successful FDA Meeting; IPF Phase 3 in 1H26

PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
RNS 9281217 ↗
05 Dec 25

PRTC's Gallop: Positive Initial Topline AML Data

PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
RNS 9279643 ↗
18 Nov 25

Holding(s) in Company
RNS 9242098 ↗
07 Nov 25

Holding(s) in Company
RNS 9220818 ↗
03 Nov 25

New LYT-200 AML Data + Update at ASH

PureTech's Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting
RNS 9209443 ↗
22 Oct 25

New IPF Data Show Benefit in Older Patients

PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
RNS 9185876 ↗
17 Oct 25

Holding(s) in Company
RNS 9178908 ↗
14 Oct 25

Holding(s) in Company
RNS 9168755 ↗
10 Oct 25

Holding(s) in Company
RNS 9164580 ↗
09 Oct 25

Holding(s) in Company
RNS 9161855 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.